Evaluation of Safety and Efficacy of Rexin-G as Intervention for Recurrent or Metastatic Sarcoma.

Trial Profile

Evaluation of Safety and Efficacy of Rexin-G as Intervention for Recurrent or Metastatic Sarcoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2011

At a glance

  • Drugs Rexin-G (Primary)
  • Indications Chondrosarcoma; Ewing's sarcoma; Leiomyosarcoma; Liposarcoma; Osteosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jun 2010 Patient number changed from 20 to 36 as reported by Epeius Biotechnologies Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top